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In women worldwide, cervical cancer ranks second in cancer inci-
dence; in women in developing countries cervical cancer ranks ﬁrst in
cancer-related deaths (Drain et al., 2002; Snijders et al., 2006). Human
papillomaviruses (HPVs) are associated with over 99% of all cervical
cancer (Snijders et al., 2006). HPVs are classiﬁed as high-risk (HR) or low-
risk (LR) depending on their pathogenicity. HR HPVs (e.g. 16, 18, 31, 33,
and 45) are commonly associated with malignancies of the cervix and
head and neck. HPVs 6 and 11 are classiﬁed as LR, and can cause condy-
loma acuminata (genital warts) (Longworth and Laimins, 2004).
The HPV life cycle is closely linked to epithelial differentiation. In
normal epithelium, proliferation occurs in the basal cell layer; as cells
migrate upwards they exit the cell cycle and differentiate. After virus
infection, viral DNA is maintained at 50–100 copies in the basal cell
layer (Hebner and Laimins, 2006; Longworth and Laimins, 2004).
When the infected cells move to the differentiated suprabasal layer
viral DNA is ampliﬁed and late genes are expressed resulting in
mature virions. Several studies indicate that both HR and LR HPVs
require the host cell to initiate cellular DNA replication (Hebner and
Laimins, 2006; Longworth and Laimins, 2004; Snijders et al., 2006; zur
Hausen, 2002). HPV E7 drives suprabasal cells into S-phase and causes
unscheduled DNA synthesis (Flores et al., 2000; Munger et al., 2001;
Collins et al., 2005); however, a recent report suggests that HPVs mayinitiate viral DNA replicationwhen the cells are in the G2 phase (Wang
et al., 2009). The E7 proteins of both HR and LR HPVs are required for
viral DNA maintenance and/or ampliﬁcation (Flores et al., 2000;
McLaughlin-Drubin et al., 2005; Oh et al., 2004; Zhang and Roman,
unpublished data).
E7 proteins consist of approximately 100 amino acid residues
and can be divided into three regions: conserved region 1 (CR1, amino
acids 2–15), CR2 (amino acids 16–38), and the C-terminal zinc-
binding region (amino acids 39–98) containing two Cys-X-X-Cys
motifs (Gage et al., 1990; Jewers et al., 1992; Munger et al., 2001). E7
proteins of HR HPV 16 and LR HPV 6 share 50% amino acid sequence
identity and 15% conservative changes (Armstrong and Roman, 1992).
Both HR and LR HPV E7 proteins bind pRb family members through
their LXCXE binding motif (Dyson et al., 1989). In vitro and in vivo
studies have revealed that HPV 16 E7, as compared to HPV 6 E7, has a
greater afﬁnity for pRb, p107, and p130 (Ciccolini et al., 1994; Gage et
al., 1990). Although HPV 6 E7 has a lower afﬁnity for binding p130
than HPV 16 E7, it is as efﬁcient in targeting p130 for degradation
(Zhang et al., 2006). Casein kinase II-mediated phosphorylation of HR
and LR HPV E7 is necessary for effective binding to and destabilization
of p130 (Genovese et al., 2008).
The pRb family of proteins (pRb, p107 and p130) plays important
roles in regulating cell-cycle control and differentiation (Gonzalez
et al., 2001; Munger et al., 2001). pRb family members are homol-
ogous in the “pocket” region, composed of sub-domains A and B and
separated by a spacer region that is highly conserved among each of
the proteins. p130 and p107 share more homology than pRb. p130
and p107 contain a region between the A and B sub-domains that is
responsible for binding to cyclin A/Cdk2 and cyclin E/Cdk2 (Classon
and Dyson, 2001; Claudio et al., 2002). pRb family members each bind
Fig. 1. Effect of Cdk inhibitors on p130 stability. HFKs were infected with parental
retrovirus LXSN (LX) or retrovirus encoding HPV 16 E7 (16 E7) or HPV 6 E7 (6E7) and
grown in C-K-SFM. Cells were then treated with 12.5 µM 3-ATA, 12.5 µM roscovitine,
50 µM ﬂavopiridol or DMSO (vehicle) as a negative control. Whole cell extracts were
harvested using EBC buffer and Western analysis performed using mouse monoclonal
antibodies to p130, pRb, GAPDH and lamin B. *, unknown protein cross-reacting with
anti-p130.
234 L. Barrow-Laing et al. / Virology 400 (2010) 233–239to speciﬁc members of the E2F family of transcription factors, which
are responsible for the transcription of E2F-responsive genes, and
hence S-phase entry (Cam and Dynlacht, 2003; Dimova and Dyson,
2005). E2F1, E2F2, and E2F3 are almost exclusively regulated by pRb,
and are referred to as activator E2Fs. p130 and p107 normally asso-
ciate with E2F4 and E2F5, repressor E2Fs; p130 associates at the G0/G1
stage of the cell cycle (Dimova and Dyson, 2005; Helin et al., 1993).
p130 levels, like the other pRb family members, are regulated in
response to the proliferative state of cells and are controlled by pro-
teolysis in a phosphorylation-dependent manner (Classon and Dyson,
2001; DeCaprio et al., 1992; Tedesco et al., 2002; Shirodkar et al.,
1992). p130 has been shown to be phosphorylated in cycling cells by
cyclin D/Cdk4 or Cdk6, cyclin A/Cdk2 and cyclin E/Cdk2 (Classon and
Dyson, 2001; Cobrinik, 2005). Cdk4/Cdk6, not Cdk2, is responsible for
targeting p130 for degradation. In cycling cells Cdk4/Cdk6 phosphor-
ylates p130 on Ser 672, resulting in a hyperphosphorylated form of
p130 that is targeted for degradation by an SCF complex (Tedesco
et al., 2002). SCF complexes are a class of ubiquitin ligase (E3) en-
zymes that recognize and polyubiquitylate substrates, usually in a
phosphorylation-dependent manner, targeting them for degradation
by the 26S proteasome (Deshaies, 1999). In contrast to pRb and p107,
p130 is phosphorylated by glycogen synthase kinase 3 (GSK3) in the
loop region in the B subdomain and thus stabilized in growth-arrested
and terminally differentiated cells (Litovchick et al., 2004).
p130 contains three nuclear localization signals (NLSs), two in the
C-terminus and one in the loop region (Chestukhin et al., 2002). In
undifferentiated cells, hypophosphorylated p130 is predominantly in
the nucleus in the G0/G1 phase of the cell cycle. In S-phase, p130 is
typically phosphorylated and transported to the cytoplasmwhere it is
targeted for degradation. Shuttling of p130 between the nucleus and
cytoplasm therefore provides ameans of regulation (Chestukhin et al.,
2002; Tedesco et al., 2002).
HPV 16 E7 has been detected in the cytoplasm and the nucleus and
is known to have both cytoplasmic and nuclear targets (Nguyen et al.,
2007; Smotkin and Wettstein, 1987; Smith-McCune et al., 1999;
Guccione et al., 2002). In support of such observations, it has been
reported that HPV 16 E7 has two NLSs and one nuclear export signal
(NES) (Knapp et al., 2009). In this study HPV 16 E7, in contrast to HPV
6 E7, was shown to either retain or relocalize p130 to the cytoplasm of
HFKs. Leptomycin B, a CRM1/exportin 1 inhibitor, did not have an
effect on HPV 16 E7 mediated p130 localization. In addition, p130 was
shown to have a shorter half-life in the nucleus of HPV 6 E7 expressing
HFKs compared to HPV 16 E7 expressing HFKs or control. These
results suggest that HPV 6 E7 and 16 E7 may target p130 for
degradation by different mechanisms.
Results
HPV E7-mediated degradation of p130 is independent of cyclin/Cdk
activity
p130 is unique in that it is the only pRb family member that is
targeted for degradation by both HPV 6 E7 and HPV 16 E7 (Zhang
et al., 2006). In uninfected cells, p130 is phosphorylated by Cdk4/6
and is recognized by an SCF–Skp2 complex for degradation in a cell-
cycle dependent manner (Tedesco et al., 2002). To ascertain whether
E7-mediated degradation of p130 is dependent on cyclin/CDK
activity, HFKs were infected with parental retrovirus LXSN, or
retrovirus encoding HPV 16 E7 or HPV 6 E7. Infected cells were
grown in keratinocyte serum-free medium (C-K-SFM) supplemented
with human recombinant epidermal growth factor and bovine
pituitary extract. Cells were then treated with 12.5 µM 3-ATA (an
inhibitor of Cdk4/6) (Kubo et al., 1999), 12.5 µM roscovitine (an
inhibitor of Cdk1, 2 and 5) (Meijer et al., 1997) or 50 µM ﬂavopiridol
(an inhibitor of Cdk 1, 2, 4, 6, and 7) (Sedlacek, 2001). Whole cell
extracts were harvested and Western analysis performed. Analysis ofthe phosphorylation status of pRb validated that the inhibitors were
functional. Hypophosphorylated and hyperphosphorylated forms of
pRb were present in cells expressing LXSN and treated with vehicle
only. However, in the presence of each of the Cdk inhibitors, only the
hypophosphorylated form of pRb was detected (Fig. 1). This result
was expected as pRb is known to be phosphorylated by cyclin D2-
Cdk4, cyclin E-Cdk2, and cyclin A-Cdk2 (Cobrinik, 2005). The
hyperphosphorylated band of p130 was lost only upon treatment
with ﬂavopiridol, but not 3-ATA nor roscovitine (Fig. 1). The steady-
state level of p130 in HPV expressing cells in the presence of each Cdk
inhibitor was compared to LXSN expressing cells. In the presence of
CDK inhibitors, both HPV 6 E7 and HPV 16 E7 retained the ability to
decrease the steady-state level of p130.
p130 localizes to the cytoplasm in keratinocytes transduced with HPV 16
E7
p130 is known to shuttle between the nucleus and cytoplasm
(Chestukhin et al., 2002). HPV E7 has been shown to alter the local-
ization of various proteins. Both HPV 6 and 16 E7 relocalize steroid
receptor coactivator 1 (SRC1) to the cytoplasm (Baldwin et al., 2006),
and HPV 16 E7 reduces the nuclear localization of p21Cip1 (Westbrook
et al., 2002). Therefore, the effect of LR and HR HPV E7 on the intra-
cellular localization of p130 was investigated. Sub-cellular fraction-
ation was performed on HFKs transduced with LXSN (control), HPV 6
E7 or HPV 16 E7. Equal-volume fractions of cytoplasmic and nuclear
extracts were obtained and Western analysis performed using
antibodies to p130, lamin B (marker for nuclear fraction) and tubulin
(marker for cytoplasmic fraction). Endogenous p130 was detected
at similar levels in the cytoplasmic and nuclear fraction in cells
expressing LXSN and HPV 6 E7. In contrast, HFKS expressing HPV
16 E7 had signiﬁcantly more p130 (three fold) in the cytoplasm
(Fig. 2).
The distribution of p130 in HFKs expressing LXSN, HPV 6 E7 or HPV
16 E7 was also determined by immunoﬂuorescence. Localization of
p130wasmostly nuclear in HFKs transducedwith LXSN and HPV 6 E7.
Fig. 2. Determination of p130 localization in nuclear and cytoplasmic fractions.
(A) HFKs were infected as in Fig. 1 and grown in C-K-SFM. Cells were harvested using
EBC buffer for whole cell extracts [WCEs (left three lanes)], or cytoplasmic and nuclear
buffers to harvest cytoplasmic fractions (CF) and nuclear fractions (NF). Equal-volume
fractions of nuclear and cytoplasmic protein were analyzed using monoclonal
antibodies to p130. *, unknown protein cross-reacting with anti-p130. Antibodies to
lamin B (nuclear marker) and GAPDH (cytoplasmic marker) were used to establish that
the fractions were enriched. A representative experiment is shown. (B) Quantity one
software was used for densitometric analysis. The nuclear fractions were then set to 1
and the ratio of cytoplasmic to nuclear p130 localization is shown. The average of
±standard deviation of 4 independent experiments is shown, (++), pb0.01.
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16 E7 (Fig. 3). This difference in the intracellular localization of p130
in the presence of HPV 16 E7 compared to that seen in LXSN or HPV
6 E7 expressing cells is consistent with sub-cellular fractionation
results.Fig. 3. Determination of p130 localization by immunoﬂuorescence. Immunoﬂuorescence stu
Cells were incubated with rabbit polyclonal antibody to p130 and visualized by immunoﬂu
shown.To test whether HPV 16 E7 relocalizes p130 to the cytoplasm via
CRM1-dependent nuclear export, HFKs expressing HPV 16 E7 were
treated with leptomycin B (LMB), a speciﬁc inhibitor of CRM1. LMB
inhibits nuclear export of the human immunodeﬁciency virus Rev
protein (Wolff et al., 1997). Therefore, we veriﬁed that the concen-
tration of LMB used was sufﬁcient to inhibit CRM1-mediated nuclear
export in HFKs by transfecting the cells with a Rev-GFP plasmid.
Treatment of transfected cells with LMB resulted in the accumulation
of Rev-GFP fusion protein in the nuclei of cells, as detected by immu-
noﬂuorescence or sub-cellular fractionation (Fig. 4A). However,
LMB treatment did not affect cytoplasmic localization of p130 in
HPV 16 E7 expressing cells as shown by sub-cellular fractionation
(Fig. 4B). Similar results were obtained by immunoﬂuorescence (data
not shown).
HPV 6 E7 can target p130 for degradation in the nucleus
In whole cell extracts, the half-life of p130 in the presence of HPV 6
E7 and HPV 16 E7 is decreased relative to control cells (Zhang et al.,
2006). The reduced half-life of p130 in the presence of HPV E7 is
restored following treatment with proteasomal inhibitors, implying
that E7 targets p130 for degradation through the proteasome pathway
(Zhang et al., 2006). To determine the half-life of p130 in the cyto-
plasmic and nuclear fractions, HPV E7 expressing cells were treated
with 0.25 mM cycloheximide, a protein synthesis inhibitor. At 0, 2, 4,
and 6 h post-treatment, p130 levels in cytoplasmic and nuclear
fractions were determined by Western blot analysis. The half-life of
p130 in the cytoplasmic fraction of HPV 6 E7 and 16 E7 expressing
cells was ∼2 h on average and shorter than control cells (Fig. 5A). In a
minority of cases, the half-life of p130 in the cytoplasm was shorter in
HPV 16 E7 cells than HPV 6 E7 cells. However in HPV 6 E7 expressing
cells, the half-life of nuclear p130 was between 3 and 4 h, less than
half as long as in control and HPV 16 E7 expressing cells (Fig. 6A).
To establish whether the decrease in p130 half-life by HPV E7 in
the nuclear and cytoplasmic fractions was due to degradation through
the proteasome pathway, HFKs were infected as above and treateddies were performed on HFKs infected as in Fig. 1 and grown on coverslips in C-K-SFM.
orescence using FITC-conjugated secondary antibody. A representative experiment is
Fig. 4. Effect of LMB on the cytoplasmic localization of p130 in HPV 16 E7 expressing
cells. (A) HFKs transfected with a plasmid encoding Rev-GFP and grown on coverslips
were treated with LMB (1 ng/ml) for 4 h. Cells were ﬁxed with 4% formaldehyde,
counterstained with 5 μg/ml of 4′-6-Diamidino-2-phenylindole (DAPI) for 7 min at
room temperature to label the nuclei, washed and mounted. Autoﬂuorescence of Rev-
GFP was detected by ﬂuorescence microscopy (above). In parallel, whole cell extracts
were harvested and Western analysis performed using antibodies to GFP (bottom).
(B) HFKs were infected as in Fig. 1 and grown in C-K-SFM to 80% conﬂuence. Cells were
then treated with LMB (1 ng/ml) for 4 h and harvested for cytoplasmic and nuclear
extracts. Equal-volume fractions of nuclear and cytoplasmic extracts were analyzed
using antibodies to p130. Antibodies against lamin B (nuclear marker) and tubulin
(cytoplasmic marker) were used as in Fig. 2. Densitometric analysis was performed
using Quantity one software and the result normalized as in Fig. 2. The averages and
standard deviation from 4 experiments are shown, (++), pb0.01.
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way inhibitor. After treatment with MG132 the ability of either E7 to
shorten the half-life of p130 in the cytoplasmic and nuclear fraction
was decreased (Figs. 5B and 6B). This suggests that although both HPV
6 E7 and HPV 16 E7 efﬁciently target p130 for proteasomal degra-
dation in the cytoplasm. HPV 6 E7 is also very efﬁcient at targeting
p130 for proteasomal degradation in the nucleus.
Discussion
HPV 16 E7 targets pRb family members for degradation. The ability
of HPV 16 E7 to target pRb for degradation in particular, is necessary
for malignant transformation (zur Hausen, 2000). HPV 6 E7 does not
cause cancer and does not affect the stability of pRb or p107 (Demers
et al., 1994; Zhang et al., 2006); however it does target p130 for deg-
radation (Zhang et al., 2006). pRb family members play a key role in
regulating progression through the cell cycle. p130 is speciﬁcally up-
regulated in G0 and is responsible for keeping cells in a differentiated
state (Cobrinik, 2005). The fact that both HR and LR E7 target p130
for degradation may indicate that p130 is important for the HPV life
cycle. Targeting p130 for degradationmay be conducive to creating an
“S-phase-like” environment (Banerjee et al., 2006; Collins et al., 2005;
Munger et al., 2001). Zhang et al., proposed that the mechanism of
degradation of p130 by HPV 16 E7 and HPV 6 E7 might be similar
based on mutational analysis (Zhang et al., 2006). However, we have
discovered HR and LR E7 may achieve this by different mechanisms.
Experiments were designed to test whether p130 degradation by
LR and HRHPV E7was dependent on cyclin/Cdk activity, since HPV E7
enhances entry of cells into the cell cycle. An increase in the quantity
of hyperphosphorylated p130 may result in enhanced degradation
of p130 (Tedesco et al., 2002). Treatment with three Cdk inhibitors,
ﬂavopiridol, 3-ATA and roscovitine, showed that both HR and LR HPV
E7 retained their ability to target p130 for degradation (Fig. 1).
Therefore, destabilization of p130 by either HPV E7may not simply be
a result of entry into the cell cycle induced by E7. Rather, our results
demonstrate that degradation of p130 by HPV E7 is independent of
cyclin/Cdk activity. Previous studies have shown that, in human
ﬁbroblasts, inhibition of Cdk4/6 results in the loss of the hyperpho-
sphorylated form of p130 (Tedesco et al., 2002). However, in E7
expressing HFKs treated with 3-ATA, a Cdk4/6 inhibitor, there was no
difference in p130 phosphorylation status as compared to E7
expressing cells treated with DMSO control (Fig. 1). Flavopiridol and
3-ATA are both active against Cdk4/6, and ﬂavopiridol and roscovitine
are active against Cdk2. Treatment with ﬂavopiridol resulted in the
abolishment of the hyperphosphorylated form of p130. This suggests
that in HFKs, hyperphosphorylated p130 may be derived from
phosphorylation by both Cdk2 and Cdk4/6.
HPV 16 E7 has been detected in the cytoplasm and in the nucleus.
In most experiments where E7 has been localized to the nucleus, E7
was visualized by immunoﬂuorescence (Smith-McCune et al., 1999;
Guccione et al., 2002), whereas when E7 has been localized to cyto-
plasm it has been visualized by western analysis of sub-cellular
fractions (Nguyen et al., 2007; Smotkin andWettstein, 1987). Here we
show that more p130 localized to the cytoplasm in the presence of
HPV 16 E7 (Figs. 2 and 3). In contrast, the localization of p130 in
the presence of HPV 6 E7 was similar to control cells (Figs. 2 and 3).
Identical results were also obtained in experiments where cells were
grown under differentiated conditions (data not shown). While the
current study was in progress, two nuclear localization signals and
one nuclear export signal were identiﬁed in HPV 16 E7 (Knapp et al.,
2009), providing further evidence that HPV 16 E7 shuttles between
the cytoplasm and nucleus. Analysis of putative NESs (NESpredictor
www.cbs.dtu.dk/) suggests that HPV 6 E7 may have an NES in the
N-terminus, in contrast to the identiﬁed NES in HPV 16 E7 which is
in the C-terminus (Knapp et al., 2009). It is possible that upon binding
to p130, a conﬁrmation change occurs in HPV 6 E7 resulting in the
Fig. 5. Decreased half-life of p130 in the cytoplasm in the presence of HPV 6 E7 and HPV 16 E7. (A) HFKs were infected as in Fig. 1. and treated with 0.25 mM cycloheximide for the
indicated times. Immunoblots of cytoplasmic extracts (top) and densitometry (bottom) from a representative experiment are shown. Cytoplasmic fractions were corrected for
tubulin and are relative to 0h. (B) Inhibition of p130 degradation byMG132. HFKs were infected as in A and treated with 0.25 mM cycloheximide plus 50 μMMG132 for the indicated
times. Immunoblots of cytoplasmic extracts (top) and densitometry (bottom) from a representative experiment are shown.
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may result in a conformational change that causes the NLS to be
inaccessible. Slight variations in the p130 localization results obtained
by sub-cellular fractionation versus immunoﬂuorescence may be due
to differences in the p130 epitopes recognized by the monoclonal
and polyclonal antisera, p130 epitopes being masked in the cytoplasm
and/or sensitivity issues with the immunoﬂuorescence assay due to
p130 being diffuse in the cytoplasm.Fig. 6. Decreased half-life of p130 in the nucleus in the presence of HPV 6 E7. (A) HFKs were i
from a representative experiment are shown. Nuclear fractions were corrected for nucleo
conducted as in Fig. 5B. Immunoblots of nuclear extracts (top) and densitometry (bottom)In HPV 16 E7 expressing cells, p130 localized mainly to the cyto-
plasm with or without LMB treatment (Fig. 5). This may be because
HPV 16 E7-mediated p130 nuclear export is CRM1-independent;
alternatively, HPV 16 E7 may cause p130 to be retained in the cyto-
plasm. In published reports, p130 cytoplasmic localization has been
shown to be insensitive to treatment with LMB (Chestukhin et al.,
2002). Additionally, although the C-terminus of HPV 16 E7 fused to
GFP was shown to accumulate in the nucleus with LMB treatmentnfected as in Fig. 5A. Immunoblots of nuclear extracts (top) and densitometry (bottom)
lin and are relative to 0h. (B) MG132 inhibits p130 degradation. Experiments were
from a representative experiment are shown.
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localization of full length HPV 16 E7 protein is LMB sensitive.
This is the ﬁrst study, to our knowledge, to address the capac-
ity of nuclear proteasomes in p130 degradation. It has long been
established that proteins can be targeted for degradation in the
cytoplasm. There is robust evidence to support that proteins can
also be targeted for degradation in the nucleus (von Mikecz, 2006).
The data presented here suggest that in the presence of HPV 16 E7,
p130 degradation is mainly mediated by cytoplasmic proteasomes.
However, for HPV 6 E7, nuclear proteasomes may also play a sig-
niﬁcant role.
HPV 16 E7 may preferentially target p130 for degradation in the
cytoplasm after sequestering it there, whereas HPV 6 E7 may have
evolved a mechanism for degrading p130 more efﬁciently in the
nucleus. However, p130 degradation does not occur exclusively in
either the nucleus or cytoplasm for HPV 6 E7 or HPV 16 E7. There may
be more than one mechanism by which p130 is targeted for
degradation by HPV 6 E7 and HPV 16 E7. Zhang et al. proposed that
the mechanism of degradation of p130 by HPV 16 E7 and HPV 6 E7
might be similar, because both HPV 16 E7 and HPV 6 E7 N-terminal
mutants lose the ability to target p130 for degradation (Zhang et al.,
2006). p600 was identiﬁed as a cellular protein that binds to both HPV
6 E7 and HPV 16 E7 (Huh et al., 2005). p600 has been speculated to be
an E3 ubiquitin ligase (Huh et al., 2005), and has been reported to bind
the N-terminus of HPV 16 E7. Therefore, p600 is a candidate
regulatory protein needed for efﬁcient p130 degradation by both
HPV 16 E7 and HPV 6 E7.
Huh et al. reported that HPV 16 E7 recruits a cullin 2 E3 ubiquitin
ligase complex that contributes to degradation of pRb. The authors
suggest that this E3 ubiquitin ligase also contributes to the
degradation of p130. HPV 6 E7 was not found to bind this cullin 2
complex (Huh et al., 2007). It is possible that HPV 6 E7 facilitates the
interaction of another E3 ubiquitin ligase with p130. Additionally,
HPV 6 E7, similar to human T-cell leukemia virus type 1 tax, may
function as a molecular bridge (Kehn et al., 2005), or as a chaperone,
like simian virus large T antigen (Srinivasan et al., 1997; Stubdal et al.,
1997), to facilitate interaction of p130 directly with the proteasome.
In conclusion, our data argue that although both LR and HR HPV
target p130 for degradation, which may be a critical aspect of their
viral life cycles, the mechanism by which the E7 proteins destabilize
p130 may be different. HPV 6 E7 seems to have evolved to co-exist
better with its host cell, causing a productive infection (a benign
condyloma) but not a lesion which is non-productive for the virus (a
carcinoma). As such, HPV 6 E7 causes less perturbation of the Rb
family circuitry than HPV 16 E7, consequently raising fewer distress
signals for the cell to counter. Since HPV 6 E7 distinguishes between
the Rb family members but HPV 16 E7 does not, the two E7 proteins
may have evolved differentmechanisms to deal with p130. By altering
the intracellular localization of p130 so that more is found in the
cytoplasm, 16 E7 has not only targeted p130 for degradation but also
effectively removed p130 from its nuclear targets.
Materials and methods
Cell culture
Human foreskin keratinocytes (HFKs) were isolated from neonatal
foreskins. The foreskin was digested with trypsin-EDTA, and kerati-
nocytes released from the tissue were plated in E medium in the
presence of mitomycin C-treated 3T3/J2 ﬁbroblasts. At 60% conﬂu-
ence, cells were subcultured in E medium on the feeder cells. At
about 80% conﬂuence, the cells were frozen. The frozen cells were
subsequently thawed in complete serum-free medium (C-K-SFM;
GIBCO/BRL) supplemented with human recombinant EGF (GIBCO/
BRL) and bovine pituitary extract (GIBCO/BRL). Where noted, cells
were treated with the following inhibitors: 0.25 mM cycloheximide(Sigma), 50 μMMG132 (Sigma), 12.5 μM 3-ATA (Alexis Biochemicals),
12.5 μMroscovitine (Sigma) or 50 μMﬂavopiridol (Sigma). Cells treated
with 3-ATA were p16 null.
Retroviruses and retroviral infection
Third-passage HFKs were grown to about 40% conﬂuence in a
10-cm-diameter dish and infected with 5 ml of the recombinant
retrovirus or parental virus in the presence of 8 µg of polybrene per
ml. After 6 h the cells were fed with C-K-SFM and kept at 37 °C with
5% CO2 for 48 h. The cells were then transferred to four 10-cm-
diameter dishes and selected with G418 (200 µg/ml) for 3 days.
Selected cells were expanded and used for experiments, generally
when at 80% conﬂuence.
Western blotting
For fractionation experiments, cell fractionation buffer (Ambion)
was used to resuspend cells and cells were placed on ice for 10 min.
Cells were pelleted at low speed to obtain supernatant, which is the
cytoplasmic fraction. 2× Laemmli buffer (4% SDS, 20% glycerol,
0.125 M Tris–HCl) was then added to the pellet, and the pellet vigor-
ously resuspended to obtain the nuclear fraction. For whole cell
extracts, cells were lysed with extraction buffer C (EBC: 50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 0.5% NP-40). Protease and phosphatase
inhibitors were added before use: protease inhibitor cocktail (Sigma),
125 µM Na3VO4 and 50 mM NaF. Protein concentrations were
determined using the Bio-Rad DC protein assay kit. For localization
experiments, equal-volume fractions of cytoplasmic and nuclear
extracts were used. Proteins were separated by 6% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS/PAGE). The proteins
were then transferred to nitrocellulose and probed with the following
antibodies: monoclonal p130 (BD Biosciences), pRb (BD Biosciences),
tubulin (Sigma), lamin B, nucleolin (Santa Cruz Biotechnology) and
GAPDH (Chemi-con). For half-life experiments equal quantity of pro-
tein was used and samples normalized to tubulin (for cytoplasmic
fractions) or nucleolin (for nuclear fractions).
Immunoﬂuorescence
Infected HFKs were grown on coverslips in C-K-SFM. Cells were
ﬁxed in 4% paraformaldehyde for 10 min. Cells were then rinsed and
permeabilized with 0.1% Triton X-100 in PBS for 10 min. The cells
were immersed in 0.1% BSA/PBS for 30 min to block nonspeciﬁc
binding. Cells were incubated with polyclonal antibody to p130
(Santa Cruz Biotechnology) diluted in 0.1% BSA/PBS for 1.5 h at room
temperature. Cells were then washed with 0.1% BSA/PBS at room
temperature, and incubated with FITC-conjugated secondary anti-
body (Santa Cruz Biotechnology). Cells were counterstained with
5 μg/ml of 4′-6-Diamidino-2-phenylindole (DAPI) for 7 min at room
temperature, washed again and mounted. Fluorescent images were
obtained by using Nikon Eclipse microscope. For experiments with
Rev-GFP plasmid (Ludwig et al., 1999), HFKs were transfected with
FuGENE 6 transfection reagent.
Statistical analysis
Student two tailed t-test was used for statistical analysis. pb0.05
was considered signiﬁcant.
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